Did Castle Biosciences beat or miss consensus estimates last quarter?

What guidance did Castle Biosciences's management provide for the next earnings period?

What were the key takeaways from Castle Biosciences's earnings call?

What is Castle Biosciences's gross profit margin?

What factors drove the changes in Castle Biosciences's revenue and profit?

What is Castle Biosciences's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Castle Biosciences year over year?

What were the key takeaways from Castle Biosciences’s earnings call?

- **Revenue Growth**: 2025 total $344.2M, driven by 9% DecisionDx-Melanoma and 86% TissueCypher growth. 
- **New Product Momentum**: AdvanceAD-Tx hits 500+ orders in 5 weeks, targeting 2027-2028 material revenue. 
- **Pipeline Expansion**: GI device (Q2 2026 enrollment) and EIS technology (Q2 2026 study) for Barrett's and atopic dermatitis. 
- **Financial Outlook**: 2026 guidance $340-350M, 69.2% gross margin, $299.5M cash. 
- **Strategic Moves**: FDA 510(k) for biomarker law compliance, 90/10% rep focus on AD, potential SCC reactivation.

**【CEO Summary Section】**
- **Q4 2025 Revenue**: $87 million, full year 2025 total $344.2 million, exceeding guidance. Core growth drivers: DecisionDx-Melanoma (+9% YoY to 39,083 reports) and TissueCypher (+86% YoY to 39,014 reports). 
- **New Product Success**: AdvanceAD-Tx launched in late 2025 with 500+ orders in first 5 weeks, targeting 2027-2028 material revenue. 
- **Pipeline Initiatives**: GI device acquisition (Previse) for Barrett's esophagus screening (Q2 2026 enrollment), SciBase EIS technology for atopic dermatitis flare prediction (Q2 2026 study). 
- **Strategic Acquisitions**: Focus on tests near reimbursement, under 100 sales team size, and complementary to current verticals. 

**【CFO Financial Commentary】**
- **2026 Guidance**: $340-350 million revenue (mid-high teens growth ex-SCC/IDgenetix). 
- **Gross Margin**: 69.2% FY2025 (down from 78.5% due to SCC loss), adjusted gross margin 79.8% (down from 82%). 
- **Expenses**: Total 2025 $387 million (+20% YoY), driven by sales (+11.8%), G&A (+19.2%), R&D stable. 
- **Cash Flow**: $64.3 million operating cash flow, $299.5 million cash as of Dec 31, 2025. 

**【Q&A Highlights】**
- **DecisionDx-Melanoma NCCN Update**: 47/58 peer-reviewed studies ignored in guidelines, 5%+ SLNB threshold unchanged. FDA 510(k) submission expected Q2 2026 for biomarker law compliance. 
- **AdvanceAD-Tx Strategy**: 150 early access accounts, 500+ orders, 90/10% melanoma/AD rep focus until ASP validation. 
- **TissueCypher Growth**: 11% patient penetration, 2,082 new clinicians in 2025, targeting private equity GI groups for uniform adoption. 
- **DecisionDx-SCC Reimbursement**: Positive draft LCD expected mid-2026, potential 2027 revenue reactivation if coverage restored.

Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript

- **$33B Market Launch**: AdvanceAD-Tx targets 13.2M U.S. atopic dermatitis patients.
- **Revenue Growth**: Q3 up 36% YoY, melanoma test hits record 10,459 reports.
- **Updated Guidance**: 2025 revenue raised to $327M-$335M.
- **Cash Flow Strength**: Positive net cash flow from operations.
- **Strategic Focus**: Melanoma growth, TissueCypher expansion, FDA melanoma approval pursuit.

**【CEO Summary Section】**
- Launched **AdvanceAD-Tx**, a first-in-class test for systemic treatment selection in moderate to severe atopic dermatitis, targeting a $33B U.S. market with 13.2M patients.
- Q3 revenue reached **$83M**, with test report volumes up 36% YoY.
- **DecisionDx-Melanoma** achieved record 10,459 reports (12% YoY growth), while **TissueCypher** grew 75% YoY to 10,609 reports.
- **SCC test volumes** remained flat due to melanoma focus, but commercial claims began.

**【CFO Financial Commentary】**
- Updated 2025 revenue guidance to **$327M-$335M** (up from $310M-$320M).
- Gross margin: 74.7% (GAAP), 76.8% (adjusted).
- Operating expenses rose 11% YoY to **$89.8M**, driven by sales and R&D growth.
- Net loss: **$0.5M**, with positive cash flow from operations.

**【Q&A Highlights】**
- **AdvanceAD-Tx** expects 10-15% Medicare patients, with phased launch in 2026.
- **SCC test** volumes stable due to clinical value, with modest commercial claims.
- **Melanoma test growth** driven by refocused sales team, targeting high single-digit YoY growth.
- **TissueCypher** penetration growing, with 75% YoY growth.
- **FDA approval** for melanoma test to support biomarker laws, no immediate SCC test stoppage.

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: $86.2M Q2 revenue, up 33% YoY in test volume, driven by TissueCypher (92% YoY) and DecisionDx-Melanoma (4% YoY).
- **Clinical Impact**: DecisionDx-Melanoma linked to 32% mortality risk reduction in largest real-world study.
- **Pipeline Momentum**: Atopic dermatitis test expected to launch by end-2025; SciBase collaboration for flare prediction in development.
- **Financial Strength**: $275.9M cash, positive cash flow, and revised 2025 revenue guidance of $310-320M (+21-26% normalized growth).
- **Strategic Focus**: FDA submission for DecisionDx-Melanoma, maintaining DecisionDx-SCC availability, and expanding GI franchise with TissueCypher.

**【CEO Summary Section】**
- **Revenue and Growth**: Q2 2025 revenue of $86.2 million, with test report volume up 33% YoY. DecisionDx-Melanoma volume grew 4% YoY, and TissueCypher grew 92% YoY.
- **Clinical Evidence**: DecisionDx-Melanoma linked to 32% reduction in mortality risk in a real-world study of 13,560 patients.
- **Pipeline Initiatives**: Collaboration with SciBase for atopic dermatitis flare prediction and internal pipeline test for atopic dermatitis treatment response, expected to launch by end-2025.
- **Balance Sheet**: $275.9 million in cash, supporting investments in clinical evidence, commercial optimization, and strategic M&A.

**【CFO Financial Commentary】**
- **Revenue Dynamics**: Net revenue decreased 1% YoY due to $12.5 million decline in dermatological tests (primarily DecisionDx-SCC), offset by $11.7 million growth in non-dermatological tests (TissueCypher).
- **Gross Margin**: Adjusted gross margin 79.5%, down from 83.2% YoY, due to higher test volumes and lab costs.
- **Operating Expenses**: Total expenses $90.4 million (+10% YoY), driven by sales/marketing (+7%), G&A (+23%), and R&D (-10%).
- **Cash Flow**: Positive net cash flow from operations ($20.8M Q2, $14.8M H1), with $275.9M in cash.
- **Guidance Update**: Full-year revenue raised to $310-320M (prev $287-297M), reflecting normalized growth of 21-26% excluding DecisionDx-SCC.

**【Q&A Key Highlights】**
- **FDA Approval for DecisionDx-Melanoma**: Breakthrough Device Designation received; FDA submission expected but timing未 disclosed.
- **DecisionDx-SCC Reimbursement**: Reconsideration requests submitted to Novitas and MolDX; Novitas accepted request, MolDX pending. Test remains available despite noncoverage.
- **TissueCypher Growth**: 92% YoY growth driven by unmet clinical need and commercial optimization; no material seasonality yet.
- **Atopic Dermatitis Test**: Internal pipeline test validated in independent cohort, targeting launch by end-2025. Reimbursement strategies include multiple parallel approaches.
- **Previse Acquisition**: Focus on multi-omics approach for Barrett's esophagus and non-endoscopic sample collection device.
- **M&A Strategy**: Prioritize tests with established reimbursement, high clinical value in adjacent areas, and pipeline synergies.


Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

- **21% Revenue Growth**: Q1 2025 revenue of $88 million driven by 117% YoY surge in TissueCypher test reports.
- **Strategic GI Expansion**: Acquired Previse to enhance Barrett's esophagus testing with methylation technology; no 2025 revenue impact expected.
- **Melanoma Focus**: 80% of derm reps now dedicated to melanoma, aligning with 8-10% YoY volume growth target for DecisionDx-Melanoma.
- **Financial Strength**: $275 million cash balance supports growth while maintaining mid-70s% gross margin for 2025.
- **Risk Management**: Continued SCC test availability despite Medicare non-coverage, leveraging $2.4M/day Medicare savings from avoided radiation therapy.


**【CEO Business Highlights】**
- **Revenue Growth**: Q1 2025 revenue reached $88 million, up 21% YoY, driven by 117% YoY growth in TissueCypher test reports (7,432 vs. 3,429 in Q1 2024). DecisionDx-Melanoma volume grew 3% QoQ and 8% YoY, with 2025 full-year volume expected to increase 8-10% YoY.
- **Strategic Acquisition**: Signed definitive agreement to acquire Previse, a GI-focused company with methylation-based technology, to expand Barrett's esophagus testing capabilities. Transaction expected to close within weeks.
- **Discontinuation of IDgenetix**: Ended mental health test due to reimbursement challenges, reallocating resources to higher-growth GI and dermatology franchises.
- **Reimbursement Update**: DecisionDx-SCC Medicare coverage ended April 24, 2025. Company will pursue reconsideration but expects no SCC revenue contribution in 2025.

**【CFO Financial Summary】**
- **Adjusted Revenue**: $87.2 million (22% YoY), excluding one-time IDgenetix amortization ($20.1 million). Full-year 2025 revenue guidance raised to $287-297 million (prior: $280-295 million).
- **Gross Margin**: 49.2% GAAP (vs. 77.9% YoY), 81.2% adjusted (vs. 80.5% YoY). Mid-70s% gross margin expected for remaining 2025 quarters.
- **Expenses**: Total operating expenses $115.9 million (54% YoY increase), driven by sales & marketing (+20.8% YoY) and G&A (+21.1% YoY). R&D expenses decreased 8.8% YoY.
- **Cash Position**: $275 million in cash, supporting growth initiatives while maintaining financial discipline.

**【Key Q&A Takeaways】**
- **Previse Integration**: No immediate revenue contribution; focus on combining TissueCypher spatialomics with Previse methylation tech for enhanced GI risk assessment.
- **Sales Force Strategy**: 65+ GI reps and 70+ derm reps; shifting focus to melanoma (80% of derm reps' time) to capitalize on strong melanoma adoption.
- **Reimbursement Risk**: SCC test will remain available despite Medicare non-coverage, driven by clinical utility (avoiding $2.4M/day in unnecessary radiation therapy costs).
- **2025 Outlook**: Excluding SCC, normalized revenue growth expected at 17-20% YoY, supported by TissueCypher expansion and melanoma ASP improvements.


Castle Biosciences (CSTL)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 revenue up 51% to $332.1M, driven by 36% test volume growth. DecisionDx-Melanoma and SCC combined grew 17% YoY. 
- **Market Penetration**: Melanoma at 28% (36,008 reports), SCC at 8% (16,348 reports), TissueCypher at 5% (20,956 reports). 
- **Risks**: DecisionDx-SCC Medicare coverage at risk post-April 2025, potentially reducing 2025 revenue. 
- **Growth Drivers**: TissueCypher expansion (salesforce doubling in 2024), melanoma focus post-SCC coverage loss. 
- **Financial Health**: 2024 gross margin 78.5%, 2025 adjusted gross margin mid-70s. Cash balance $293.1M, positive 2025 cash flow expected. 


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue of $86.3M, up 51% YoY to $332.1M. Total test volume grew 36% YoY. DecisionDx-Melanoma and SCC combined grew 17% YoY. DecisionDx-Melanoma test reports reached 36,008 in 2024 (8% YoY growth), with 28% market penetration. DecisionDx-SCC test reports grew 43% YoY to 16,348, with 8% market penetration. TissueCypher grew 130% YoY to 20,956 reports. 
- **Pipeline Momentum**: IDgenetix test volumes declining due to strategic focus shift. SCC Medicare coverage at risk post-April 2025, potentially reducing 2025 revenue. Mental health business under review. 
- **Growth Drivers**: TissueCypher salesforce expansion, unmet clinical need in Barrett's esophagus. Dermatology team focused on melanoma post-SCC coverage loss. 

**【CFO Financial Commentary】**
- **Revenue Performance**: 2024 total revenue $332.1M (51% YoY), driven by test volume growth and higher ASP for DecisionDx-SCC. 5-year CAGR 52%. 2025 guidance: $280-295M (excluding SCC Medicare coverage). 
- **Gross Margin**: Q4 2024 gross margin 76.2%, full year 78.5%. 2025 adjusted gross margin expected mid-70s due to SCC coverage loss. 
- **Expenses**: 2024 operating expenses $323.4M (14% YoY), driven by sales & marketing (+9%), G&A (+15%), and R&D. 2025 expects continued investment in TissueCypher. 
- **Cash Flow**: 2024 net cash from operations $64.9M. 2025 expects positive net cash flow. Cash balance $293.1M as of Q4 2024. 

**【Q&A Highlights】**
- **SCC Reimbursement Risk**: Medicare coverage for DecisionDx-SCC may end April 2025, reducing 2025 revenue. Exploring alternative reimbursement pathways and non-Medicare payer opportunities. 
- **Salesforce Strategy**: Post-SCC coverage loss, dermatology team to focus 100% on melanoma. TissueCypher salesforce expansion to ~60-80 reps by maturity. 
- **Pipeline Updates**: Atopic dermatitis test validation study ongoing; launch potential late 2025. Reimbursement strategy to be determined post-launch. 
- **Market Dynamics**: Private derms prefer melanoma test, while academic centers await guideline inclusion. TissueCypher adoption supported by AGA guidelines. 
- **Risk Management**: Contingency plans for SCC coverage loss include reallocating resources to melanoma and TissueCypher. 


Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Castle Biosciences (CSTL)-4 Nov 24-2024 Q3 Earnings call transcript

Castle Biosciences (CSTL)-5 Aug 24-2024 Q2 Earnings call transcript

Castle Biosciences (CSTL)-2 May 24-2024 Q1 Earnings call transcript

- **Revenue Surge**: 60% YoY growth to $219.8M, driven by 59% test volume increase. Q4 revenue up 72% YoY to $66.1M.
- **Clinical Impact**: Tests linked to 29% lower melanoma mortality and $972M Medicare savings by avoiding unnecessary radiation.
- **Pipeline Momentum**: TissueCypher (+300%), IDgenetix (+200%), and new inflammatory skin disease test (2025 launch) driving diversification.
- **Key Risk**: DecisionDx-SCC Medicare coverage uncertain; potential $15M 2024 revenue impact if coverage denied.
- **Financial Health**: Improved EBITDA (-$4.4M vs -$42.6M YoY). 2024 revenue guidance $235-240M. Cash position $243M.

**【CEO Summary Section】**
- **Revenue Growth**: 2023 total revenue of $219.8 million, up 60% YoY, driven by 59% test volume growth to 70,429 reports. Q4 revenue $66.1 million (+72% YoY). Core dermatology tests (DecisionDx-melanoma, SCC) grew 33% to 44,772 reports. TissueCypher (Barrett's Esophagus) grew 300% to 9,100 reports. IDgenetix (mental health) grew 200% to 10,921 reports.
- **Clinical Impact**: DecisionDx-melanoma linked to 29% lower melanoma-specific mortality. DecisionDx-SCC shown to save $972M annually in Medicare costs by avoiding unnecessary radiation therapy.
- **Pipeline Progress**: Inflammatory skin disease test (atopic dermatitis/psoriasis) expected to launch late 2025 if development successful. 2024 plans include modest TissueCypher commercial team expansion.

**【CFO Financial Commentary】**
- **Financial Highlights**: Full year 2023 GAAP net loss $57.5M (-15% vs 2022), with Q4 loss $2.6M (vs $20.6M YoY). Adjusted EBITDA improved to -$4.4M (vs -$42.6M YoY). Cash position $243.1M, up $13M QoQ. 2024 revenue guidance $235-240M, driven by core test growth.
- **Cost Management**: Operating expenses $287.8M (+38% YoY) due to personnel costs. Gross margin 75% (2022: 71%). 2024 expects continued investment in R&D and commercial teams.
- **Liquidity**: Q1 2024 expected to be cash use quarter due to annual bonuses. Remain confident in long-term cash generation.

**【Q&A Key Highlights】**
- **Reimbursement Risk**: DecisionDx-SCC Medicare coverage uncertain as Novitas draft LCD excludes test. If finalized, could reduce 2024 revenue by ~$15M. Company may limit test availability if not reimbursed.
- **Gross Margin Concerns**: CFO states gross margin would decline if any test loses coverage. Current 80%+ adjusted gross margin assumes all tests reimbursed.
- **Pipeline Updates**: TissueCypher gastroenterology team expansion planned. IDgenetix mental health test seeing strong adoption despite no direct sales force.
- **2025 Cash Target**: Reiterate goal of positive cash flow from operations by 2025, through disciplined expense management and revenue growth.

Actual				0.03	-0.08	-0.23	-0.23	-0.17	-0.35	-0.47	-0.25	-0.97	-0.06	-0.77	-0.78	-1.1	-0.7	-0.26	-0.1	-0.09	0.31	0.08	0.32	-0.9	0.15	-0.02	-0.08
Forecast				-0.148	-0.3975	-0.1145	-0.1217	-0.2344	-0.3323	-0.405	-0.4705	-0.7071	-0.7618	-0.8806	-0.8376	-0.8905	-0.9151	-0.7641	-0.5624	-0.332	-0.2687	-0.004	0.0471	-0.0694	-0.5311	-0.5213	-0.2586
Surprise	0.00%	0.00%	0.00%	+120.27%	+79.87%	-100.87%	-88.99%	+27.47%	-5.33%	-16.05%	+46.87%	-37.18%	+92.12%	+12.56%	+6.88%	-23.53%	+23.51%	+65.97%	+82.22%	+72.89%	+215.37%	+2100.00%	+579.41%	-1196.83%	+128.24%	+96.16%	+69.06%

CSTL

CSTL fundamentals

CSTL Q4 2025 Earnings

Earnings Call

You can ask Aime

CSTL

CSTL fundamentals

CSTL Q4 2025 Earnings

Earnings Call

CSTL Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

CSTL Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

CSTL Earnings Call Summary for Q2/20254:30 PM on Aug 4, 2025

CSTL Earnings Call Summary for Q1/20254:30 PM on May 5, 2025

CSTL Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime